11.27
1.25 (12.48%)
| Previous Close | 10.02 |
| Volume | 3,005,888 |
| Price / Sales | 4.13 |
| Price / Book | 1.37 |
| 52 Weeks Range |
| Profit Margin | -198.84% |
| Operating Margin (TTM) | -182.09% |
| Diluted EPS (TTM) | -8.91 |
| Quarterly Revenue Growth (YOY) | 27.30% |
| Total Debt/Equity (MRQ) | 67.12% |
| Current Ratio (MRQ) | 4.88 |
| Operating Cash Flow (TTM) | -281.85 M |
| Levered Free Cash Flow (TTM) | -185.65 M |
| Return on Assets (TTM) | -16.99% |
| Return on Equity (TTM) | -57.76% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Bullish |
| Biotechnology (Global) | Mixed | Bullish | |
| Stock | Ginkgo Bioworks Holdings, Inc. | Mixed | Bearish |
AIStockmoo Score
| Analyst Consensus | NA |
| Insider Activity | -3.0 |
| Price Volatility | -4.5 |
| Technical Moving Averages | 1.0 |
| Technical Oscillators | -0.5 |
| Relative Valuation | NA |
| Financial Health | NA |
| Macro Environment | 0.0 |
| AI Insight | NA |
| Weighted Average | -1.40 |
Select this tab to load the latest available analysis.
|
Ginkgo Bioworks Holdings Inc is the platform for cell programming, providing flexible, end-to-end services that solve challenges for organizations across diverse markets, from food and agriculture to pharmaceuticals to industrial and specialty chemicals. The Company reorganized its operations into two operating and reportable segments: Cell Engineering engaged in providing biological R&D services for customers across a range of industries and Biosecurity that provides services to government and commercial customers to identify, monitor, prevent, mitigate, and ultimately protect humanity from biological threats. The maximum of revenue is from Cell Engineering Segment. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Value |
| % Held by Insiders | 6.88% |
| % Held by Institutions | 77.96% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Erste Asset Management Gmbh | 30 Jun 2026 | 2,536,939 |
| Anchorage Capital Group, L.L.C. | 30 Jun 2026 | 1,746,363 |
| Forbes J M & Co Llp | 30 Sep 2026 | 977,371 |
No data within this time range.
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| CANTON BARRY | - | 10.07 | -41,172 | -414,602 |
| COEN STEVEN P. | - | 10.07 | -766 | -7,714 |
| KELLY JASON R | - | 10.07 | -45,682 | -460,018 |
| SHETTY RESHMA P. | - | 10.07 | -41,172 | -414,602 |
| Aggregate Net Quantity | -128,792 | |||
| Aggregate Net Value ($) | -1,296,935 | |||
| Aggregate Avg. Buy ($) | - | |||
| Aggregate Avg. Sell ($) | 10.07 | |||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| KELLY JASON R | Officer | 19 Oct 2026 | Sell (-) | 45,682 | 10.07 | 460,018 |
| SHETTY RESHMA P. | Officer | 19 Oct 2026 | Sell (-) | 22,369 | 10.07 | 225,256 |
| SHETTY RESHMA P. | Officer | 19 Oct 2026 | Sell (-) | 18,803 | 10.07 | 189,346 |
| CANTON BARRY | 19 Oct 2026 | Sell (-) | 18,803 | 10.07 | 189,346 | |
| CANTON BARRY | 19 Oct 2026 | Sell (-) | 22,369 | 10.07 | 225,256 | |
| COEN STEVEN P. | Officer | 19 Oct 2026 | Sell (-) | 766 | 10.07 | 7,714 |
| KELLY JASON R | Officer | 16 Oct 2026 | Option execute | 81,484 | - | - |
| SHETTY RESHMA P. | Officer | 16 Oct 2026 | Option execute | 39,898 | - | - |
| SHETTY RESHMA P. | Officer | 16 Oct 2026 | Option execute | 36,564 | - | - |
| CANTON BARRY | 16 Oct 2026 | Option execute | 36,564 | - | - | |
| CANTON BARRY | 16 Oct 2026 | Option execute | 39,898 | - | - | |
| COEN STEVEN P. | Officer | 16 Oct 2026 | Option execute | 1,486 | - | - |
| Show more | ||||||
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |